Amgen, Novartis sue each other over migraine drug Aimovig
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen gets FDA approval for migraine drug Aimovig
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen clinical trial shows promising results for migraine drug Aimovig
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen announces positive results for migraine drug
Thousand Oaks-based biotech giant Amgen announced positive data from a phase 3 study of a new migraine drug co-developed with competitor Novartis. Amgen said in a news release that, after 12 weeks, Erenumab showed a significant reduction in monthly migraine days in patients with episodic migraines treated with Erenumab compared with a placebo. In the Read More →
